BioELife Corp.
LITH · OTC
9/30/2019 | 6/30/2019 | 3/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.01 | -0.02 | 0.00 |
| FCF Yield | -3.75% | -4.68% | -4.78% | -11.75% |
| EV / EBITDA | -21.86 | -6.66 | 11.91 | -1.87 |
| Quality | ||||
| ROIC | -300.26% | -39.13% | -73.78% | 48.60% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.26 | -0.43 | 0.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -20.94% | 13.66% | 52.18% | -322.01% |
| Safety | ||||
| Net Debt / EBITDA | 0.31 | 0.21 | 2.94 | -0.54 |
| Interest Coverage | 0.00 | -4.66 | -3.47 | -2.26 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,122.97 | -5,022.97 | -252,327.45 | -14,769.68 |